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Abstract 
Background 
Carotid-femoral pulse wave velocity (cfPWV) is widely used in epidemiological studies to assess 
central arterial stiffness. However, despite being superior to traditional risk factors in predicting 
cardiovascular outcomes, cfPWV is not routinely used in clinical practice. cfPWV assessments 
require applanation of the carotid artery, which can be cumbersome, and subject-level factors, 
including carotid artery plaque, may confound the measurements. Heart-femoral PWV (hfPWV) 
may be a suitable alternative measure of central arterial stiffness. 
Objectives 
To estimate the strength of the agreement between hfPWV and cfPWV. 
Methods 
We evaluated 4,133 older-aged (75.2 [5.0] years) African American and Caucasian adults in the 
community-based Atherosclerosis Risk in Communities (ARIC) Study. cfPWV and hfPWV were 
measured using an automated cardiovascular screening device. Agreement between the two 
measurements was determined using Pearson’s correlation coefficient (r), standard error of 
estimate (SEE), and Bland-Altman analysis. 
Results 
There was strong (r >0.7) agreement between hfPWV and cfPWV (r= 0.83, 95%CI: 0.82, 0.84). 
While the mean cfPWV (11.5 m/s [SD: 3.0]) and hfPWV (11.5 m/s [SD: 2.3]) were comparable, 
the SEE was 1.7 m/s. Inspection of the Bland-Altman plot revealed greater variability and bias for 
higher PWV values, with higher PWV further away from the regression line. 
Discussion 
Findings suggest good agreement between hfPWV and cfPWV. hfPWV is a simpler alternative 
to cfPWV which is less likely to be confounded by subject-level factors. Considering the greater 
variability for higher PWV values, further work is warranted to determine the importance of local 
artery mechanics to both measures. 
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Introduction 
Pulse wave velocity (PWV) is widely used in epidemiological studies to assess arterial stiffness 
and estimate cardiovascular disease (CVD) risk.[1] PWV is calculated by measuring the transit 
time (TT) of the arterial waveform between two points of a measured distance.[2] The mostly 
widely studied path is between the carotid and femoral arteries (the cfPWV), which represents 
the aorto-illiac pathway. International reference norms have been established for population, age, 
and risk factor strata [3] for cfPWV, a measure found to be strongly associated with the risk of CV 
events. [4]. However, cfPWV assessments typically require applanation of the carotid artery, 
which can be technically challenging in certain populations, including persons who are obese and 
those with advanced carotid artery atherosclerosis.[5] Further, cfPWV assessment is not 
consistent with the path of blood flow from the aortic arch to the carotid artery, which is not 
included in measurement of the distance between the carotid and femoral measurement points. 
In order to adjust for this, an assumption is made about the timing of the pressure wave travelling  
to the carotid artery and this is used to adjust the measure accordingly.[6] An alternative measure 
of central arterial stiffness is the heart-femoral PWV (hfPWV). 
 
For cfPWV assessments, TT is recorded as the time between the foot of the carotid pressure 
waveform and the foot of the femoral pressure waveform. For hfPWV, TT can be calculated as 
the time between the ventricular ejection, determined from an electrocardiogram and/or a 
phonocardiogram, and the foot of the femoral pressure waveform. The hfPWV approach confers 
a number of potential advantages over cfPWV: (i) it is simpler to conduct, as the measurement is 
not dependent on applanation of the carotid artery; (ii) the measurement path is consistent with 
the blood flow path; and (iii) the presence of carotid plaque is unlikely to confound measurements. 
To date, of the few studies on hfPWV[7–14] only one directly compared hfPWV to cfPWV.[6] 
While the previous study reported a strong correlation (r = 0.81) between the two measures, 
systemic bias was not explored, the study did not include women, and the age range of the 
population was narrow (40-49 years). Therefore, the primary aim of the current study was to 
determine the association between hfPWV and cfPWV using a well-characterized population of 
older men and women from the Atherosclerosis Risk in Communities (ARIC) Study cohort. The 
second aim was to compare the strength of associations of hfPWV and cfPWV with traditional 
vascular risk factors, such as age, smoking status, body mass index (BMI), blood pressure (BP), 




This observational study is reported in accordance with STROBE (STrengthening the Reporting 
of OBservational studies in Epidemiology) guidelines.[15] Participants provided written informed 
consent, and the study was approved by the Institutional Review Boards at all field centers, 
coordinating center, and central labs and reading centers. Data availability and detailed policies 
for requesting Atherosclerosis Risk in Communities (ARIC) data can be found at 
https://sites.cscc.unc.edu/aric/pubs-policies-and-forms-pg. ARIC data can be also obtained from 
the NHLBI BioLINCC repository (https://biolincc. nhlbi.nih.gov/home/). 
 
Participants 
The ARIC Study is a population-based, longitudinal study of 15,792 participants aged 45–64 years 
enrolled between 1987 and 1989 from 4 US communities (Forsyth County, North Carolina; 
Jackson, Mississippi; Minneapolis, Minnesota; and Washington County, Maryland). Details of the 
baseline visit have been previously described.[16] Prior to exclusions, the current analysis 
includes 5,638 participants who attended visit 5 between 2011 and 2013 and had PWV measured.  
 
Exclusions 
We excluded participants with the following conditions due to concerns over the quality of the 
PWV measures: BMI ≥40 kg/m2, major arrhythmias (Minnesota codes 8-1-3, 8-3-1, and 8-3-2), 
Minnesota code 8-1-2 with evidence of biased PWV waveforms, aortic aneurysms, abdominal 
aorta ≥5 cm, history of aortic or peripheral revascularization or aortic graft, aortic stenosis, and 
moderate or greater aortic regurgitation. Additionally, we excluded participants whose race was 
other than Caucasian or African American (due to small sample size),  with missing PWV or 
vascular risk factor data, as well as those with outlying PWV values, defined as PWV values 3 
standard deviations above or below the mean.  
 
Study Design 
Participants were asked not to consume food or drink, and refrain from tobacco and vigorous 
physical activity after midnight prior to the clinic visit or for 8 hours prior to the visit. Visit 5 study 
examination included interviewer-administered questionnaires to obtain demographic data, 
medical history and lifestyle information, blood and urine collection, and assessment of vascular 




Pulse Wave Velocity 
Technicians measured cfPWV and hfPWV following a standardized protocol with the automated 
cardiovascular screening device VP-1000 Plus (Omron, Kyoto, Japan)[17] after participants were 
supine for 5–10 minutes. The device simultaneously measured electrocardiogram, 
phonocardiogram, bilateral brachial and ankle blood pressures and carotid and femoral arterial 
pulse waves.  A minimum of two measurements were taken per participant and the last 2 
measurements were averaged. The validity and reliability of the automatic device for measuring 
PWV have been described previously.[18,19] Quality assurance for PWV included central training 
and recertification, quarterly equipment calibration, and ongoing quality control reviews by one of 
the authors (H.T.) on a stratified random sample of 40 records per month with feedback provided 
to technicians. Approximately 78% of records were considered optimal quality, 17% were good 
quality, 3% were acceptable, and none were poor or unacceptable.  
 
Carotid-Femoral Pulse Wave Velocity. The cfPWV was calculated using the equation: distance 
/ TT. The distance from the carotid to the femoral artery was directly measured with a segmometer 
(Rosscraft, Surrey, Canada) and calculated as the carotid to femoral distance minus the distance 
between the suprasternal notch to the carotid applanation site. To calculate TT, arterial 
waveforms were simultaneously acquired for 30 seconds by applanation tonometry sensors 
attached on the left common carotid artery (via neck collar) and left common femoral artery.  
 
Heart-Femoral Pulse Wave Velocity. The hfPWV was calculated from the equation: distance/ 
TT. The distance from the heart to the femoral artery was automatically calculated by the VP-
1000 Plus using a height-based equation: 0.5643 x height - 18.381.[20] To calculate TT, the time 
interval between the S2 heart sound on phonocardiogram and the dicrotic notch of the brachial 
pulse wave, and time interval between the brachial and femoral artery pulse waves were 
recorded. The sum of these time intervals gives the time required for pulse waves to travel from 
the heart (aortic orifice) to the femoral artery.  
 
Covariate Measurements 
Demographics. Age was calculated from date of birth. Sex and race were self-reported. History 
of smoking was self-reported and analyzed as dichotomous (current versus noncurrent). 
 
Anthropometrics. Body weight was measured to the nearest 0.1kg, and height was recorded to 
the nearest centimeter. BMI was calculated using height and weight. 
 
BP. Three seated BP measurements were obtained after a 5-minute rest using an oscillometric 
automated sphygmomanometer (Omron HEM-907 XL, Omron, Kyoto, Japan), and the average 
of the last 2 measurements was used.  
 
Blood Markers. Blood samples were obtained following a standardized venipuncture protocol 
and shipped weekly to ARIC central laboratories where assays for total cholesterol, high-density 
lipoprotein (HDL) cholesterol, triglycerides, and fasting glucose concentration were performed. 
Total plasma cholesterol concentrations were determined enzymatically [21] using a Cobas-Bio 
analyzer with reagents purchased from Boehringer Mannheim Biochemicals, (Indianapolis, IN). 
Plasma low-density lipoprotein (LDL) cholesterol, concentration was calculated using the 
Friedewald equation,[22] and HDL concentrations were measured using the method of Warnick 
et al.[23]  
 
Medications. Participants were asked to bring all prescription and nonprescription medications 
taken within 2 weeks. That information was transcribed and categorized using MediSPAN 
prescription codes and classified into medication categories.  
 
Prevalent Cardiovascular Diseases. Hypertension was defined as systolic BP (SBP) ≥140 mm 
Hg, diastolic BP (DBP) ≥90 mm Hg, or antihypertensive medication use. Prevalent coronary heart 
disease and stroke were defined by ARIC cohort surveillance data at Visit 5. Prevalent heart 
failure was defined as physician reported heart failure or a hospitalization discharge with an ICD 
code 428.x.  
 
Statistical Analyses 
Statistical analyses were performed using R Statistical Software. The α-level was set a priori for 
all statistical procedures at α = 0.05. Participant characteristics were estimated as means and 
SDs, or frequencies and percent, where appropriate. Cumulative frequency and Q-Q plots were 
used to compare the distributions of cfPWV and hfPWV. 
 
Initially, linear regression models included sex and race interaction terms to determine their 
importance to the agreement between hfPWV and cfPWV. If sex or race interaction term(s) were 
significant, subsequent models were stratified by sex and/or race. Next, linearity was explored by 
specifying the hfPWV quadratic term. Subsequently, the association between the two 
measurements was determined by calculating the Pearson product-moment correlation (r) and 
standard error of estimate (SEE). Although there is no universal criterion, in general, r value 
estimates of <0.2, 0.2-0.4, 0.4–0.70, 0.70–0.9 and >0.9 indicate negligible, weak, moderate, 
strong, and very strong agreement, respectively.[24] The SEE represents the average distance 
that the observed values fall from the regression line, with smaller values indicating that the 
observations are closer to the fitted line. The SEE was calculated using the equation: SD x √(1-
r2),[25,26] whereby SD is the standard deviation of the criterion measure and r is the Pearson 
product-moment correlation between test and criterion devices. The relative standard error (RSE) 
was also calculated by expressing SEE relative to the mean of cfPWV. Bland–Altman plots  were 
generated to permit visual analysis of the uniformity of error over the range of participant 
measurement values.[27] 
 
Associations between risk factors with cfPWV and hfPWV were evaluated using multivariable 
linear regression. Independent variables included sex, age, BMI, current smoking, DBP, SBP, 
heart rate, glucose, HDL cholesterol, LDL cholesterol, and triglycerides. Models were adjusted for 
study center, prevalent diabetes, prevalent cardiovascular disease (hypertension, coronary heart 
disease, heart failure, stroke), and medication count (β-blockers, α-blockers, calcium channel 
blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers). 
We retained variables significantly associated with cfPWV or hfPWV (P < 0.1). We report β 




Descriptive characteristics are reported in Table 1. Following exclusions, the sample included 
4,133 participants between the ages of 66 and 90 years, of which 60% were women and 22% 
were African American. Of the original 5,683 participants, 1550 were excluded because they had 
one or more of the exclusion conditions (n = 576): PWV values were 3 SDs above or below the 
mean (n = 59), missing PWV data (n = 572), race other than Caucasian or African American 
(n=13), missing risk factor data (n = 128), and missing covariates (n=202). Men had higher cfPWV 
(0.3 m/s, P = 0.002) and hfPWV (0.3 m/s, P = <0.001) values compared to women, though 
distributions were similar for each sex (Suppl. Figure 1). 
 
Table S1. Linear and non-linear regression estimates for pulse-wave velocity  
(hfPWV) versus carotid-femoral pulse wave velocity (hfPWV), stratified by sex 
           
 
 
                                Figures 1A and 1B. 
 
Agreement between cfPWV and hfPWV 
In a model regressing hfPWV against cfPWV, the race interaction term was non-significant (P = 
0.600) but the sex interaction term was significant (P <0.001). Subsequently, linearity was 
explored by specifying the hfPWV quadratic term for each sex (Suppl. Table 1). For combined 
sexes, the quadratic term was significant (P = <0.001), but the change in R2 was marginal (∆R2 = 
0.001). Similarly, for women the quadratic term was significant (P = <0.005), but the change in R2 
was marginal (∆R2 = <0.001). For men, the change in R2 was non-significant (∆R2 = <0.001, P = 
0.206). Thus, we used linear models for subsequent analysis. 
 
Correlations between cfPWV and hfPWV are reported in Table 2. There was strong (r >0.7) 
agreement between hfPWV and cfPWV for the combined sexes (r = 0.83, 95%CI: 0.82 to 0.84, 
Figure 1A), in women (r = 0.85, 95%CI: 0.84 to 86 Figure 2A), and in men (r = 0.82, 95%CI: 0.81 
to 84, Figure 2C). For the combined sexes, inspection of the regression (Figure 1A) and Bland-
Altman (Figure 1B and Suppl. Table 2) plots indicate greater variability and bias for higher PWV 
values. Similarly, inspection of the regression and Bland-Altman plots for women (Figures 1A-B 
and Suppl. Table 2) and men (Figures 1C-D) indicate greater variability and bias for higher PWV 
values. This greater variability for higher PWV values explains why the SEE ranged from 1.6 to 
1.7 m/s (Table 2) even though the mean bias from Bland-Altman analysis was 0.02 m/s (95%CI: 
0.03 to 0.07) for the combined sexes, -0.31 m/s (95%CI: -0.39 – 0.23) for men, and 0.24 m/s 
(95%CI: 0.18 to 0.30) for women. 
 
                 Table S2. Bland-Altman estimates for heart-femoral pulse velocity (hPWV) versus  
                 carotid-femoral pulse wave velocity (cfPWV), stratified by sex. Women=2,489, Men=1,644 








                     Figures 2A, 2B, 2C and 2D. 
 
              
 
 
Correlations between cfPWV and hfPWV with traditional vascular risk 
Stepwise regression analysis was used to identify which covariates associated with cfPWV and 
hfPWV (see Suppl. Table 3 for full, unadjusted models). For the combined sexes and for women, 
cfPWV was positively associated with age, SBP, heart rate, and fasting glucose, and negatively 
associated with BMI, DBP and HDL-cholesterol. For men, cfPWV did not significantly associate 
with fasting glucose or HDL-cholesterol levels. Across sexes, the highest standardized regression 
coefficients were between cfPWV and SBP, heart rate and then age. Except for DBP, covariate 
associations were consistent between cfPWV and hfPWV, and the highest standardized 
regression coefficients were observed for the same covariates (SBP, heart rate and age). 
 
Table S3. Multivariable  




This study investigated the agreement between hfPWV and cfPWV and compared which 
traditional vascular risk factors correlated with hfPWV and cfPWV. Our findings show strong (r 
>0.7) agreement between hfPWV and cfPWV. Additionally, both hfPWV and cfPWV positively 
correlated with age, SBP, heart rate, and fasting glucose and negatively correlated with BMI and 
HDL-cholesterol. The findings suggest that hfPWV may be a suitable alternative to cfPWV. 
However, in interpreting the findings, the following should be considered: (i) while the strength of 
the association between hfPWV and cfPWV was equitable across sexes, the sex interaction term 
was significant; and (ii) for both sexes, there was greater variability for higher PWV values – 
suggesting that hfPWV and cfPWV are less comparable at higher PWV values.  
 
 
Limitations and Strengths 
The strengths and limitations of this study need to be addressed to best contextualize the findings. 
First, our population consisted of older adults, limiting the generalizability of our findings to 
younger populations. Additionally, since the African American members of the ARIC cohort 
predominantly reside in Jackson, MS, the observed associations may not generalize to African 
Americans as a demographic group. Second, the study population may be biased through 
predominate inclusion of participants who have survived from baseline (1987-1989) to the time of 
the Visit 5 examination (2011-2013) and are healthier as compared to those who did not 
participate in the visit. Last, as with any observational study, we cannot rule out the possibility of 
residual confounding - though we did include several important confounders in our models. A 
major strength is that this is the largest study to directly and simultaneous compare hfPWV and 
cfPWV assessments. 
 
Comparison to Literature 
A study by Choo et al.,[6] which included 784 Korean men and is the only other study to directly 
compare hfPWV to cfPWV, reported a comparable association (r = 0.81) to that reported in the 
current study (r = 0.83). The current study extends these previous findings through the recruitment 
of participants with a greater age range (66 to 90 years), and participants with a greater range of 
hfPWV (4.3 to 18.9 m/s) and cfPWV (3.0 to 23.0 m/s) values. Further, the previous study [6] did 
not include women, nor was systemic bias explored. For the current study, sex did interact with 
the agreement between hfPWV and cfPWV. By way of explanation, vascular structural and 
functional properties differ between the sexes,[28,29] as does the relationship between HR and 
cfPWV.[30] These differences could affect the relationship between central PWV measures. 
However, it should be considered that the differences in the hfPWV vs. cfPWV slopes between 
women and men were small (1.14 vs 1.02 m/s, respectively, Figure 2A-B). Additionally, the faster 
slope for the women was likely driven by greater error variance at higher PWV values, as evident 
from the greater Bland-Altman slope for the women compared to men (-3.3 vs. -3.18 m/s). 
 
The bias at higher PWV values may have been driven by several sources, including measurement 
of distance between the two pulse waveform sites, and the likelihood of carotid plaque in 
participants with high PWV values. The distance for calculating hfPWV was estimated using a 
height-based formula, which could have introduced error. Further error may have been introduced 
by the measurement of the distance between carotid and femoral sites, which was measured over 
the body and may not reflect the actual length of the aorta. However, neither of these sources of 
error likely explain the greater variability for higher PWV values. It is conceivable that carotid 
plaque was more prevalent in participants with a higher PWV value. The presence of 
atherosclerotic plaques, commonly found in carotid arteries, influences local mechanics and 
vessel elasticity.[31] The effect of plaque on local mechanics may explain why the lowest quartile 
of cfPWV - and not the highest quartile as may be expected - has been reported to most strongly 
associate with stroke,[11] and why local carotid arterial stiffness is associated with stroke 
independent of cfPWV.[32] 
 
Both hfPWV and cfPWV positively correlated with age, SBP, heart rate, and fasting glucose and 
negatively correlated with BMI and HDL-cholesterol. However, glucose and HDL-cholesterol were 
significantly associated with both PWV measures for women, but not men. In particular, there was 
a stronger association between HDL-cholesterol and both PWV measures for women, which may 
indicate that HDL-cholesterol has a greater protective effect in women. [33] The finding of a 
negative association between BMI and both PWV measures across sexes is consistent with 
cross-sectional studies examining associations between BMI with hfPWV [6] or cfPWV.[6,34] 
Obesity is associated with higher cardiac output and lower peripheral vascular resistance [35,36] 
that could contribute to a lower PWV. It is important to note that longitudinal studies consistently 
report a positive relationship between adiposity and central PWV progression.[37–40] 
Collectively, these finding suggest that elevated adiposity may be associated with a lower central 
PWV at baseline, but that the change over time is accelerated in participants with greater 
adiposity.  
 
Besides the study by Choo et al., [6] seven other studies have reported on hfPWV and 
cardiovascular-related outcomes,[7–13] of which three also included cfPWV.[10–12] Collectively, 
these studies report that hfPWV is positively associated with age,[7] N-terminal pro b-type 
natriuretic peptide (NT-proBNP),[12] blood pressure,[7] diabetes,[7] albumin-creatinine ratio 
(ACR)[10] and aldosterone,[9] and negatively associated with either estimated glomerular 
filtration rate (eGFR).[8,10,12] The comparative studies report that both cfPWV and hfPWV are 
positively associated with proBNP[12] and ACR,[10] and negatively associated with eGFR,[10] 
but that the highest quartile of cfPWV was most strongly associated with CVD, especially heart 
failure.[11] It should be acknowledged that the later study[11] and the current study utilized ARIC 
participants, and we do report greater variability between hfPWV and cfPWV at higher PWV 
values. As reasoned above, these findings may suggest that higher cfPWV values indicate the 
presence of carotid artery plaque and/or altered carotid mechanics, which is robustly associated 
with heart failure.[42,43] Further work is required to determine the importance of local artery 
mechanics to both cfPWV and hfPWV. 
 
Implications 
To date, despite being superior to traditional risk factors in predicting CVD outcomes,[4] cfPWV 
is not routinely used in clinical practice. One likely reason for low clinical uptake is the requirement 
of carotid artery applanation, which can be cumbersome to both technicians and participants. 
hfPWV is a simpler alternative which is also less likely to be confounded by subject-level factors, 
including the presence of plaque. The current study extends the scant hfPWV literature by 
reporting good agreement between hfPWV and cfPWV, and a similar relationship between the 
two measures with traditional vascular risk factors. In addition to hfPWV, emerging PWV 
measures should be considered. One study recently compared cfPWV to heart-thigh PWV,[14] 
using a oscillometric cuff placed around the thigh, and previous studies have compared cfPWV 
to brachial-thigh PWV, [44,45] using oscillometric cuffs placed around both sites. For both of these 
techniques there was moderate to strong (R = 0.59 – 0.75) agreement with cfPWV. Further work 
is required to compare these PWV measures in terms of predicting and tracking CVD, and to 
identifying strategies for implementing into clinical practice. 
 
Conclusions 
Findings suggest that hfPWV may be a suitable alternative to cfPWV due to high agreement. 
Considering there was greater variability for higher PWV values, and the presence of plaque is 
more likely for high PWV values, further work is warranted to determine the importance of local 
artery mechanics to both cfPWV and hfPWV. 
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Figures and Tables 
TABLE 1. Descriptive characteristics of ARIC visit 5 participants, stratified by sex. 
 
  Total Women Men 
  n = 4133 n = 2489 n= 1644 
Continuous Variables Mean (SD) Mean (SD) Mean (SD) 
Age (years) 75.2 (5.0) 75.0 (5.0) 75.4 (5.0) 
Body Mass Index (kg/m2) 27.9 (4.5) 27.7 (4.8) 28.1 (3.9) 
Diastolic blood pressure (mm Hg) 66.1 (10.3) 65.9 (10.2) 66.5 (10.5) 
Systolic blood pressure (mm Hg) 130.0 (17.3) 131.2 (17.8) 128.3 (16.3) 
Heart rate (bpm) 64.5 (10.5) 65.9 (10.4) 62.3 (10.2) 
Fasting glucose (mmol/l) 6.2 (1.5) 6.1 (1.4) 6.4 (1.6) 
LDL (mmol/l) 2.7 (0.9) 2.9 (0.9) 2.5 (0.9) 
HDL (mmol/l) 1.4 (0.4) 1.5 (0.4) 1.2 (0.3) 
Triglycerides (mmol/l) 1.4 (0.6) 1.4 (0.6) 1.4 (0.7) 
Categorical Variables  No. (%) No. (%) No. (%) 
Race             
African American 917 (22.2) 619 (24.9) 298 (18.1) 
White 3216 (77.8) 1870 (75.1) 1346 (81.9) 
Current smoker 229 (5.5) 137 (5.5) 92 (5.6) 
Prevalent Cardiovascular Disease             
# Prevalent CVD (Median, Q1, Q3) (1) (1, 1) (1) (1, 1) (1) (1, 2) 
Hypertension 2991 (72.4) 1823 (73.2) 1168 (71.1) 
Coronary heart disease 567 (13.7) 198 (8.0) 369 (22.5) 
Heart failure 425 (10.3) 226 (9.1) 199 (12.1) 
Stroke 118 (2.9) 65 (2.6) 53 (3.2) 
Medication use             
# Medications (Median, Q1, Q3) (1) (0, 2) (1) (0, 2) (1) (0, 2) 
β-Blocker 1154 (27.9) 675 (27.1) 479 (29.1) 
α-Blocker  136 (3.3) 79 (3.2) 57 (3.5) 
Diuretic  1588 (38.4) 1043 (41.9) 545 (33.2) 
ACE Inhibitor 1246 (30.2) 645 (25.9) 601 (36.6) 
ANG II receptor blocker  675 (16.3) 452 (18.2) 223 (13.6) 
Calcium channel blocker 1006 (24.3) 626 (25.2) 380 (23.1) 
 
Abbreviations: Q1, 25th quartile; Q3, 75th quartile 
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TABLE 2. Comparison of heart-femoral pulse-wave velocity (hfPWV) and carotid-femoral pulse wave velocity (cfPWV), stratified by 
sex. 
 
    cfPWV hfPWV r SEE (m/s) RSE (%) 
   n =  Mean (SD) Mean (SD) (95% CI) (95% CI) (95% CI) 
Total 4133 11.5 (3.0) 11.5 (2.3) 0.83 (0.82 - 0.84) 1.7 (1.6 - 1.7) 14.4 (14.0 - 14.8) 
Women 2489 11.4 (3.0) 11.2 (2.2) 0.85 (0.84 - 0.86) 1.6 (1.5 - 1.6) 13.8 (13.3 - 14.1) 
Men 1644 11.7 (3.0) 12.0 (2.4) 0.82 (0.81 - 0.84) 1.7 (1.6 - 1.7) 14.5 (13.8 - 14.9) 


















TABLE 3. Multivariable linear regression associations with pulse-wave velocity (hfPWV) and carotid-femoral pulse wave velocity 
(cfPWV) 
 
  Total   Women   Men 
  n = 4,133   n= 2,489   n= 1,644 
  β  Std. β SE P   β  Std. β SE P   β  Std. β SE P 
cfPWV   R2 =  0.22       R2 =  0.25       R2 =  0.20   
Age (years) 0.11 0.18 0.01 <0.001   0.10 0.17 0.01 <0.001   0.10 0.17 0.01 <0.001 
Body Mass Index (kg/m2) -0.06 -0.09 0.01 <0.001   -0.06 -0.10 0.01 <0.001   -0.06 -0.07 0.02 0.002 
Diastolic blood pressure (mm Hg) -0.02 -0.08 0.01 <0.001   -0.03 -0.09 0.01 <0.001   -0.03 -0.10 0.01 0.001 
Systolic blood pressure (mm Hg) 0.05 0.32 0.00 <0.001   0.06 0.33 0.00 <0.001   0.06 0.33 0.01 <0.001 
Heart rate (bpm) 0.06 0.22 0.00 <0.001   0.07 0.23 0.01 0.040   0.07 0.24 0.01 <0.001 
Fasting glucose (mmol/l) 0.11 0.05 0.03 0.002   0.10 0.04 0.05 <0.001   0.09 0.05 0.05 0.080 
HDL (mmol/l) -0.81 -0.10 0.12 <0.001   -0.60 -0.07 0.15 <0.001   -0.40 -0.04 0.24 0.098 
hfPWV   R2 =  0.20       R2 =  0.24       R2 =  0.18   
Age (years) 0.08 0.18 0.01 <0.001   0.08 0.18 0.01 <0.001   0.08 0.17 0.01 <0.001 
Body Mass Index (kg/m2) -0.08 -0.15 0.01 <0.001   -0.08 -0.17 0.01 <0.001   -0.06 -0.10 0.02 <0.001 
Systolic blood pressure (mm Hg) 0.04 0.29 0.00 <0.001   0.04 0.32 0.00 <0.001   0.04 0.29 0.00 <0.001 
Heart rate (bpm) 0.03 0.14 0.00 <0.001   0.04 0.18 0.00 <0.001   0.04 0.18 0.01 <0.001 
Fasting glucose (mmol/l) 0.11 0.07 0.03 <0.001   0.10 0.06 0.04 0.006   0.07 0.04 0.04 0.109 
HDL (mmol/l) -0.84 -0.13 0.10 <0.001   -0.39 -0.06 0.12 <0.001   -0.11 -0.01 0.20 0.563 
Adjustments: race, field center, prevalent cardiovascular diseases (hypertension, coronary heart disease, stroke, heart failure), and medications 
(β-blockers, α-blockers, calcium channel, blockers, diuretics). 
Abbreviations: β, beta coefficient; HDL, high-density lipoprotein cholesterol; SE, standard error; std. β, standardized beta coefficient 
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FIGURE 1. (A) regression and (B) Bland-Altman plots for heart-femoral pulse velocity (hfPWV) 






FIGURE 2. (A+C) regression and (B+D) Bland-Altman plots for heart-femoral pulse velocity 
(hfPWV) versus carotid-femoral pulse wave velocity (cfPWV), stratified by sex. Women n = 2,489, 





TABLE S1. Linear and non-linear regression estimates for pulse-wave velocity (hfPWV) versus 
carotid-femoral pulse wave velocity (cfPWV) and pulse-wave velocity (hfPWV), stratified by sex 







TABLE S2. Bland-Altman estimates for heart-femoral pulse velocity (hfPWV) versus carotid-
femoral pulse wave velocity (cfPWV), stratified by sex. Women=2,489, men=1,644. 
Abbreviations: β, beta coefficient; LCI, lower 95% confidence interval; UCI, upper 95% confidence interval 





TABLE S3. Multivariable linear regression associations with pulse-wave velocity (hfPWV) and 
carotid-femoral pulse wave velocity (cfPWV) 
Abbreviations: β, beta coefficient; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein 
















FIGURE S1. Distribution of carotid-femoral pulse wave velocity (cfPWV) for women (A) and 
men, and distribution of heart-femoral pulse wave velocity (hfPWV) for women (C) and men (D).            
 
